MGX-102

MGX-102 is a discovery-stage single-domain antibody (sdAb) therapeutic being developed by Mabgenex for the treatment of snake envenomation. The drug is designed to neutralize key toxic components of snake venom, specifically targeting phospholipase A2 (PLA2) and bungarotoxin (Btx). By utilizing the single-domain antibody format (often referred to as nanobodies), MGX-102 aims to provide a more stable and potent alternative to traditional equine- or ovine-derived antivenoms. This modality potentially offers improved tissue penetration and a reduced risk of adverse immunological reactions, such as serum sickness or anaphylaxis, which are common with conventional antivenom treatments.